CAMBRIDGE, Mass. — Days before his company is expected to win approval of the most expensive drug ever, the head of Swiss drug giant Novartis (NVS) said Wednesday he could justify charging up to $5 million for the revolutionary treatment for a rare genetic disease, but it will end up being priced at a fraction of that.

Speaking at the company’s biomedical research institute, Novartis CEO Vas Narasimhan wouldn’t disclose the price of the drug, called Zolgensma, until the government approves it, probably by the end of the month. Zolgensma treats spinal muscular atrophy, or SMA, a deadly neurodegenerative disease.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • How can the cost of SMA1 be calculated at “~ $2M p.a over 10 years”, when NONE of these patients live to even 5 years.
    Cost-effectiveness is truly important, but the calculations quoted make utter nonsense of reality.
    STAT – surely you can do better?

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy